Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics
- PDF / 340,831 Bytes
- 13 Pages / 595.276 x 790.866 pts Page_size
- 58 Downloads / 172 Views
(0123456789().,-volV) (0123456789().,-volV)
ORIGINAL ARTICLE
Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics Lubomı´r Skladany´1 • Marian Oltman2 • Sonˇa Franˇkova´3 • Sylvia Drazˇilova´4,8 • Petr Husa5 • Jan Sˇperl3 • Va´clav Hejda6 • Petr Urba´nek7 • Svetlana Adamcova´-Selcˇanova´1 • Martin Janicˇko8 • Pavol Kristian9 • Viera Kupcˇova´10 • Marek Ra´c11 • Ivan Schre´ter9 • Ladislav Vira´g9 • Adriana Lipta´kova´12 Miriam Ondra´sˇova´13 • Peter Jarcˇusˇka8
•
Received: 14 April 2020 / Revised: 18 September 2020 / Accepted: 22 September 2020 Swiss School of Public Health (SSPH+) 2020
Abstract Objectives The MOSAIC study gathered data on chronic hepatitis C virus (HCV) infection and its treatment in various countries worldwide. Here we summarise patient and HCV characteristics in the Czech Republic and Slovakia. Methods MOSAIC was an observational study that included patients with chronic HCV infection untreated at the time of enrolment. Study collected and descriptively analysed patient demographics, disease stage and viral characteristics. Data were collected between February 2014 to October 2014.
Lubomı´r Skladany´ has served as a consultant to companies Astellas, Abbvie, Gilead, and MSD. He has also received research funding from Abbvie, and speaker fees from Abbvie, MSD, and Gilead. Marian Oltman has served as a consultant to Abbvie, Gilead and MSD and has received research funding and speaker fees from Abbvie, Gilead, and MSD. Sonˇa Franˇkova´ has served a consultant to Gilead Sciences, Abbvie, MSD and received speaker fees from Gilead Sciences, Abbvie, and MSD. Sylvia Drazˇilova´ has served as a consultant to Abbvie, Gilead, and MSD, has received research funding from Abbvie and has received speaker fees from Abbvie and Gilead. Petr Husa has served as a consultant to Abbvie, and has received research funding and speaker fees from Abbvie. Jan Sˇperl has served as a consultant to companies Abbvie, Gilead, and MSD. He has also received research funding from Gilead, and speaker fees from Abbvie, MSD, and Gilead. Va´clav Hejda has served as a consultant to MSD, Abbvie and received speakers fee from Abbvie, MSD, and Gilead. Petr Urba´nek has served as a consultant to Abbvie, Gilead and MSD, has received research funding from Abbvie and has received speaker fees from Abbvie and Gilead. Svetlana Adamcova´-Selcˇanova´ has served as a consultant to companies Astellas, Abbvie, and MSD. She has also received research funding from Abbvie and speaker fees from Abbvie, MSD, and Gilead. Martin Janicˇko declares no conflict of interest pertinent to the submitted manuscript. Pavol Kristian has served as a consultant to Abbvie, MSD, and Gilead Sciences Slovakia and has received research funding and speaker fees from Abbvie, MSD, and Gilead Sciences Slovakia.
Viera Kupcˇova´ has served as a consultant to Abbvie and has received speaker fees from Abbvie. Marek Ra´c has served a consultant to Promed CS, has received no research funding, has received spe
Data Loading...
